@article{KoenigRammeFaustetal.2022,
  author    = {Koenig, Leopold and Ramme, Anja Patricia and Faust, Daniel and Mayer, Manuela and Fl{\"o}tke, Tobias and Gerhartl, Anna and Brachner, Andreas and Neuhaus, Winfried and Appelt-Menzel, Antje and Metzger, Marco and Marx, Uwe and Dehne, Eva-Maria},
  title     = {A human stem cell-derived brain-liver chip for assessing blood-brain-barrier permeation of pharmaceutical drugs},
  series = {Cells},
  volume    = {11},
  journal   = {Cells},
  number    = {20},
  issn      = {2073-4409},
  doi       = {10.3390/cells11203295},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-290375},
  year      = {2022},
  abstract  = {Significant advancements in the field of preclinical in vitro blood-brain barrier (BBB) models have been achieved in recent years, by developing monolayer-based culture systems towards complex multi-cellular assays. The coupling of those models with other relevant organoid systems to integrate the investigation of blood-brain barrier permeation in the larger picture of drug distribution and metabolization is still missing. Here, we report for the first time the combination of a human induced pluripotent stem cell (hiPSC)-derived blood-brain barrier model with a cortical brain and a liver spheroid model from the same donor in a closed microfluidic system (MPS). The two model compounds atenolol and propranolol were used to measure permeation at the blood-brain barrier and to assess metabolization. Both substances showed an in vivo-like permeation behavior and were metabolized in vitro. Therefore, the novel multi-organ system enabled not only the measurement of parent compound concentrations but also of metabolite distribution at the blood-brain barrier.},
  language  = {en}
}
@article{GordonDaneshianBouwstraetal.2015,
  author    = {Gordon, Sarah and Daneshian, Mardas and Bouwstra, Joke and Caloni, Francesca and Constant, Samuel and Davies, Donna E. and Dandekar, Gudrun and Guzman, Carlos A. and Fabian, Eric and Haltner, Eleonore and Hartung, Thomas and Hasiwa, Nina and Hayden, Patrick and Kandarova, Helena and Khare, Sangeeta and Krug, Harald F. and Kneuer, Carsten and Leist, Marcel and Lian, Guoping and Marx, Uwe and Metzger, Marco and Ott, Katharina and Prieto, Pilar and Roberts, Michael S. and Roggen, Erwin L. and Tralau, Tewes and van den Braak, Claudia and Walles, Heike and Lehr, Claus-Michael},
  title     = {Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology},
  series = {ALTEX: Alternatives to Animal Experimentation},
  volume    = {32},
  journal   = {ALTEX: Alternatives to Animal Experimentation},
  number    = {4},
  doi       = {10.14573/altex.1510051},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-144275},
  pages     = {327-378},
  year      = {2015},
  abstract  = {Models of the outer epithelia of the human body namely the skin, the intestine and the lung have found valid applications in both research and industrial settings as attractive alternatives to animal testing. A variety of approaches to model these barriers are currently employed in such fields, ranging from the utilization of ex vivo tissue to reconstructed in vitro models, and further to chip-based technologies, synthetic membrane systems and, of increasing current interest, in silico modeling approaches. An international group of experts in the field of epithelial barriers was convened from academia, industry and regulatory bodies to present both the current state of the art of non-animal models of the skin, intestinal and pulmonary barriers in their various fields of application, and to discuss research-based, industry-driven and regulatory-relevant future directions for both the development of new models and the refinement of existing test methods. Issues of model relevance and preference, validation and standardization, acceptance, and the need for simplicity versus complexity were focal themes of the discussions. The outcomes of workshop presentations and discussions, in relation to both current status and future directions in the utilization and development of epithelial barrier models, are presented by the attending experts in the current report.},
  language  = {en}
}